NCT02379520 2026-04-15
HESTIA
Baylor College of Medicine
Phase 1 Completed
Clinical Trials
30 trialsNCT02693535 2026-04-02
TAPUR
American Society of Clinical Oncology
Phase 2 Recruiting
NCT06031233 2026-03-30
MINUTE
Isala
Phase 4 Recruiting
NCT03388190 2026-02-13
METIMMOX
University Hospital, Akershus
Phase 2 Completed
NCT02813135 2026-01-16
ESMART
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1/2 Recruiting
NCT02812667 2025-11-12
Nivolumab in Combination With Plinabulin in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC)
University of California, San Diego
Phase 1 Completed
NCT03963518 2025-10-06
SURROGATE-ICI
Institut Bergonié
Completed
NCT04095208 2025-10-02
CONGRATS
Institut Bergonié
Phase 2 Active not recruiting
NCT06237920 2025-09-03
TURANDORELA
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT03697564 2025-08-06
Nivolumab + Cabiralizumab + Gemcitabine in Patients With Stage IV Pancreatic Cancer
University of California, San Diego
Phase 2 Completed
NCT04572451 2025-08-01
Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma
University of Pittsburgh
Phase 1 Recruiting
NCT03387761 2025-03-05
NABUCCO
The Netherlands Cancer Institute
Phase 1 Completed
NCT03296137 2024-10-26
Adoptive Cell Therapy Across Cancer Diagnoses
Herlev Hospital
Phase 1/2 Completed
NCT05655715 2024-10-16
CheckPRO
Herlev and Gentofte Hospital
Phase 2 Completed
NCT03409198 2024-10-15
ICON
Oslo University Hospital
Phase 2 Completed
NCT02664181 2024-09-03
PRECISE
Case Comprehensive Cancer Center
Phase 2 Completed
NCT03299946 2024-09-03
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1 Completed
NCT03190265 2024-08-07
Study of CRS-207, Nivolumab, and Ipilimumab With or Without GVAX Pancreas Vaccine (With Cy) in Patients With Pancreatic Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 2 Completed
NCT05153304 2024-06-10
Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers
University of California, San Diego
Phase 1/2 Withdrawn
NCT05964101 2024-05-21
GALAXY-1
The First Affiliated Hospital of Guangzhou Medical University
Phase 2 Recruiting
NCT04300244 2024-02-29
NIPU
Oslo University Hospital
Phase 2 Active not recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05150236 2023-12-15
ANZUP2001
Australian and New Zealand Urogenital and Prostate Cancer Trials Group
Phase 2 Unknown
NCT04984733 2023-11-29
ELEVATE
University of Southampton
Phase 2 Recruiting
NCT05767684 2023-08-25
Neoantigen Derived DCs as Cancer Treatment
National Health Research Institutes, Taiwan
Phase 1 Unknown
NCT04801966 2023-05-10
TAILOR
Peter MacCallum Cancer Centre, Australia
Phase NA Terminated
NCT05175235 2023-03-03
Nivolumab and Pembrolizumab Dose Optimisation in Solid Tumours With CURATE.AI Platform and Sequential ctDNA Measurements
National University Hospital, Singapore
Phase 1/2 Unknown
NCT03431948 2023-02-16
C4-MOSART
University of Chicago
Phase 1 Completed
NCT03792724 2019-01-03
INTRUST
Clinica Universidad de Navarra, Universidad de Navarra
Phase 1/2 Unknown
NCT02962804 2018-03-05
Combination Radiation and PD-1 Inhibition in Metastatic or Recurrent Renal Cell Carcinoma (RCC)
University of Kansas Medical Center
Phase 2 Withdrawn